Fulgent Genetics reports Q4 EPS 4c, consensus (37c)

Reports Q4 revenue $76.21M, consensus $75.39M. Ming Hsieh, chairperson of the board of directors and CEO, said, “I am pleased with the progress of our business in 2024. Laboratory Services exhibited strong growth for the year. In Therapeutics Development, we now have a clinical pipeline, with FID-007 continuing to progress in a Phase 2 trial and FID-022 cleared by the U.S. FDA to begin a Phase 1 trial.”